ClinicalTrials.gg
Active, not recruitingNCT04141150Updated Jun 15, 2023

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

A Phase 2 interventional study of [18F]APN-1607 in Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease and Healthy Volunteers, sponsored by APRINOIA Therapeutics, LLC. Active, not recruiting at 3 sites in United States. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by APRINOIA Therapeutics, LLC · Phase 2, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
574th of 1,611
130 · median 73
Started
2022
with 130 others
Phase 2
360 of 1,942
50 open now
Primary completion
2024-09
later than 12 of 446 live
Registered
1,145th of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 574th largest by planned enrollment of the 1,611 interventional ones that give a count, is one of 131 that started in 2022, is one of 360 in phase 2, reaches primary completion later than 12 of the 446 other live ones, and was the 1,145th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.

Read the detailed description

The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.

The specific objectives are:

  • To expand the safety and tolerability profile for the administration of [18F]APN-1607 and PET scanning.
  • To assess regional patterns of [18F]APN-1607 uptake.
  • To determine the Braak stage equivalent reflected by [18F]APN-1607 uptake patterns.
  • To evaluate the relationship between regional measures of [18F]APN-1607 uptake and demographic characteristics, eg, age and gender; biological characteristics, eg, apolipoprotein E epsilon 4 (APOE4) carrier status and measures of Aβ burden; and clinical characteristics, eg, measurements of AD disease severity, such as National Institute on Aging and Alzheimer's Association (NIA-AA) diagnosis, Mini-mental Status Exam (MMSE) score, and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAScog).
03

Conditions studied

  • Alzheimer's Disease
  • Mild Cognitive Impairment Due to Alzheimer's Disease
  • Healthy Volunteers

Browse trials for

Keywords

  • AD
  • MDAD
  • HV
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for All Subjects:

  1. Males or females aged 50 to 85 years, inclusive.
  2. Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or for at least 1 year (ie, 12 consecutive months with no menses without an alternative medical cause) or, if they are of , must commit to using a barrier method or to abstinence for the duration of the study and must have a negative pregnancy test.
  3. Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method (ie, condom), or to abstinence for the study duration.
  4. Male subjects must not donate sperm for the study duration.
  5. Willing and able to participate in all study procedures.

Additional Inclusion Criteria for Healthy Subjects:

  1. Written must be obtained before any assessment is performed.
  2. Medically healthy with no finding on physical examination, laboratory profiles, VS, or at screening and upon reporting for the [18F]APN-1607 Imaging Visit.
  3. No cognitive impairment based on neuropsychological battery and as judged by the Investigator.
  4. No first-degree family history of early-onset AD or other neurodegenerative disease associated with dementia (prior to age 65).
  5. Has a clinical dementia rating (CDR) score of 0.
  6. Has an score ≥ 27.
  7. The subject has an appropriate informant to accompany the subject to screening to provide information for the CDR testing. In the event that the informant cannot accompany the subject to screening, the interview may be performed via phone, at the discretion of the site Investigator.

Additional Inclusion Criteria for Subjects with MDAD:

  1. Written informed consent must be obtained before any assessment is performed.
  2. Must meet all of the clinical criteria for MCI according to NIA-AA criteria, including lack of functional impairment sufficient to warrant a diagnosis of dementia.
  3. Has a CDR score = 0.5.
  4. Has an MMSE score between 24 and 30, inclusive.
  5. Has a positive amyloid PET scan obtained during screening or in the past 1 year.
  6. Medications taken for symptomatic treatment of AD must have been stable for at least 30 days prior to screening and throughout the completion of the neuropsychological battery.
  7. The subject has an appropriate informant to provide information for the CDR and accompany the subject for any visits, if required for subject or staff comfort or safety.

Additional Inclusion Criteria for Subjects with AD Dementia:

  1. Written informed consent must be obtained before any assessment is performed. If in the Investigator's opinion the subject lacks capacity to consent, participation is only possible if the subject has a legally authorized representative (LAR) or responsible next-of-kin and that individual provides written informed consent in accordance with local regulations and guidelines and the rules of the applicable independent ethics committee (IEC)/institutional review board (IRB). When written informed consent is provided by a LAR or responsible next of kin, the subject's assent must also be obtained and documented. For subjects judged lacking capacity to consent, next-of-kin consent in lieu of LAR consent is only allowed where permitted by local laws and regulations.
  2. Has a diagnosis of AD dementia according to NIA-AA criteria, including significant impairment of activities of daily living.
  3. Has a CDR score ≥ 0.5 at screening.
  4. Has an MMSE score between 10 and 26, inclusive.
  5. Has a positive amyloid PET scan obtained during screening or in the past 1 year.
  6. Medications taken for symptomatic treatment of AD must have been stable for 30 days prior to screening and throughout the completion of the neuropsychological battery.
  7. The subject has an appropriate informant to accompany the subject on all visits and provide information for the CDR.

Exclusion Criteria for All Subjects:

  1. Current or prior history (within the last 10 years) of alcohol or drug abuse.
  2. Known to [18F]APN-1607 or its
  3. Clinically significant active or unstable medical illness or planned surgical procedures during the study period. History of cancer (other than non-melanoma skin cancers or stable, local prostate cancer), unless without evidence of active disease within the last 3 years and without ongoing medical or surgical therapy.
  4. Laboratory tests with clinically significant abnormalities or a history or evidence of clinically significant unstable medical illness.
  5. Has received any drug or device for any purpose within 30 days of screening (or 5 halflives of the drug, whichever is longer), has received a non-biologic investigational treatment (ie, small molecule) for AD or other cause of dementia within the last 3 months (or 5 half-lives of the drug, whichever is longer), or received a non-vaccine treatment (ie, monoclonal antibody) for the treatment of AD or other cause of dementia within the last 6 months, or has ever received a vaccine for the treatment of AD or other cause of dementia.
  6. Prior participation in other research protocols or clinical care in the last year in which the additional radiation exposure expected from participation in this clinical study will together exceed local guidelines, eg, above an effective dose of 50 mSv in the US.
  7. Pregnant, lactating or breastfeeding.
  8. Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease.
  9. Unsuitable veins for repeated venipuncture.
  10. MRI exclusion criteria include: Findings that may be responsible for the neurologic status of the patient such as significant evidence of cerebrovascular disease (more than two lacunar infarcts, any territorial infarct >1cm3, or deep white matter abnormality corresponding to an overall Fazekas scale of 3 with at least one confluent hyperintense lesion on the fluid-attenuated inversion recovery (FLAIR) sequence that is ≥20 mm in any dimension), infectious disease, space-occupying lesions, normal pressure hydrocephalus or any other abnormalities associated with central nervous system (CNS) disease. For subjects with MDAD or AD dementia, there may be evidence of atrophy compatible with AD.
  11. Implants, such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI unless an acceptable MRI obtained in the 1 year prior to participation in the study is used.
  12. Signs or symptoms suggestive of active Coronavirus disease 2019 (COVID-19) and/or confirmed diagnosis of COVID-19, or positive COVID-19 polymerase chain reaction (PCR) test in the previous 2 weeks. These subjects should not be enrolled until 4 weeks after full recovery and further assessment by the Investigator per institutional guidelines. A subject with a known history of being exposed to someone who was diagnosed of COVID-19, during the prior 4 weeks, should not be enrolled unless the infection is excluded by local practice or institution.

Exclusion Criteria for Healthy Subjects:

  1. Meets criteria for a diagnosis of MDAD or dementia or has ever had such a diagnosis.
  2. Has ever received treatment with a drug for cognitive impairment or dementia.

Exclusion Criteria for Subjects with MDAD:

  1. Meets criteria for a diagnosis of dementia due to AD.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    [18F]APN-1607

    Subjects will undergo PET imaging using \[18F\]APN-1607.

    Drug: [18F]APN-1607

Interventions

  • In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.

06

What researchers measure

Primary outcomes

  1. Assessment of [18F]APN-1607 Uptake Patterns by Regional SUVR Values

    Regional \[18F\]APN-1607 uptake patterns will be assessed in regions of interest (ROIs) and an iROI that are relevant to AD pathology. \[18F\]APN-1607 uptake patterns identified by regional analysis will be compared among healthy subjects, subjects with MDAD, and subjects with AD dementia. Standard uptake value (SUV) will be calculated for each ROI, and SUVRs will be calculated by normalizing SUV of ROIs to the SUV of relevant reference region. Mean and standard deviation of \[18F\]APN-1607 uptake (ie, SUVR) will be calculated across healthy, MDAD and AD dementia cohorts. Differences between groups will be tested at a P-value of 0.05 using statistical analyses methods (eg, unpaired t-test, ANOVA).

    Time frame: Day 7

Secondary outcomes

  1. Number of Adverse Events (AEs)

    Measured by participants reporting AEs through non-directive questioning of the subject at each visit during the study or when volunteered by participants during or between visits.

    Time frame: Day 7

  2. Number of Serious Adverse Events (SAEs)

    Measured by participants reporting adverse events classified as serious

    Time frame: Day 7

  3. Number of participants with vital sign abnormalities

    Vital Sign measurements will include blood pressure, pulse rate, respiratory rate and body temperature.

    Time frame: Day 7

  4. Number of participants with ECG abnormalities

    Measured by 12-lead electrocardiogram

    Time frame: Day 7

  5. Number of participants with clinical laboratory abnormalities

    Measured by blood and urine analysis

    Time frame: Day 7

07

Study locations

3 sites
  • Invicro (Site 100), 60 Temple Street, 8th Floor
    New Haven, Connecticut 06510, United States
  • The NeuroCognitive Institute (Site 103), 111 Howard Blvd., Suite 204
    Mount Arlington, New Jersey 07856, United States
  • Columbia University Irving Center for Clinical and Translational Research (Site 105), 622 West 168th Street, PH-10th Floor
    New York, New York 10032, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Sep 2024, 30 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 30 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2019
First posted
Oct 28, 2019
StartActual
Mar 22, 2022
Primary completionEst.
Sep 2024
CompletionEst.
Feb 2025
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04141150
Lead sponsor
APRINOIA Therapeutics, LLC
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Mar 22, 2022
Primary completion
Sep 2024 (estimated)
Completion
Feb 2025 (estimated)
Last update
Jun 15, 2023

Study contacts

David Russell, M.D., Ph.D
principal investigator · Invicro

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florzolotau F-18

Start the discussion